Trial Profile
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications Cognition disorders; COVID-19 respiratory infection; Dyspnoea; Fatigue; Sleep disorders
- Focus Therapeutic Use
- Sponsors CytoDyn
- 01 Dec 2021 According to a CytoDyn media release, the company has submitted for peer review yesterday.
- 30 Jul 2021 Status changed from active, no longer recruiting to completed.
- 21 Jun 2021 Results published in the Media Release